In vitro activities of ceftazidime/avibactam alone or in combination with antibiotics against multidrug-resistant Acinetobacter baumannii isolates

被引:16
|
作者
Kara, Emel Mataraci [1 ]
Yilmaz, Mesut [2 ]
Celik, Berna Ozbek [1 ]
机构
[1] Istanbul Univ, Fac Pharm, Dept Pharmaceut Microbiol, TR-34116 Istanbul, Turkey
[2] Istanbul Medipol Univ, Fac Med, Dept Infect Dis & Clin Microbiol, Istanbul, Turkey
关键词
Ceftazidime/avibactam; Combination; beta-Lactam inhibitors; Gram-negative; Synergy; TIME-KILL; COLISTIN; TIGECYCLINE; INFECTIONS; EMERGENCE; IMIPENEM; AGENTS;
D O I
10.1016/j.jgar.2018.12.004
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: Infections caused by multidrug-resistant (MDR) Acinetobacter baumannii (A. baumannii) are a growing problem because of the limited options for treatment. The number of antimicrobials that are currently being developed is still insufficient to control this global threat. Combination therapies of antibiotics with different antimicrobial mechanisms have been proposed as the best options for treating MDR A. baumannii infections. The objective of this study was to investigate the in-vitro effectiveness of ceftazidime/avibactam alone or in combination with antibiotics against MDR A. baumannii isolates using time-kill assays. Methods: Forty clinical MDR strains were screened, and minimum inhibitory concentrations (MIC) and minimum bactericidal concentrations (MBC) of ceftazidime/avibactam, colistin, levofloxacin, meropenem, tigecycline, and tobramycin were determined by microbroth dilution method. The in-vitro synergistic activities of ceftazidime/avibactam with antibiotic combinations were determined by time-kill assays at 1 x MIC and 4 x MIC against five MDR A. baumannii isolates. Results: Based on MIC results, all isolates of A. baumannii were resistant to ceftazidime/avibactam, except for AB-5. All isolates were found to be resistant to meropenem and levofloxacin. At 4 x MIC, all of the tested antibiotics showed bactericidal effect (>= 3 log(10)killing). The synergistic activities of ceftazidime/avibactam + colistin, ceftazidime/avibactam + tobramycin and ceftazidime/avibactam + tigecycline combinations at 1 x MIC were observed against studied 5/5, 4/5 and 4/5 strains, respectively. Furthermore, all of the tested combinations at 4 x MIC were additive at 24 h. No antagonism was observed. Conclusions: The findings of this study suggest that a significant bactericidal effect was seen with all tested combinations. These findings present significant implications for antibiotic choice for the treatment of infections caused by MDR A. baumannii. (C) 2018 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:137 / 141
页数:5
相关论文
共 50 条
  • [1] In vitro activity of minocycline alone or in combination in multidrug-resistant Acinetobacter baumannii isolates
    Rodriguez, Carlos Hernan
    Nastro, Marcela
    Vay, Carlos
    Famiglietti, Angela
    [J]. JOURNAL OF MEDICAL MICROBIOLOGY, 2015, 64 : 1196 - 1200
  • [2] Pharmacodynamics of tigecycline alone and in combination with colistin against clinical isolates of multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model
    Cai, Xuejiu
    Yang, Zhen
    Dai, Jianqiang
    Chen, Kun
    Zhang, Liangda
    Ni, Wentao
    Wei, Chuanqi
    Cui, Junchang
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2017, 49 (05) : 609 - 616
  • [3] In vitro Effects of Tigecycline in Combination with Other Antimicrobials against Multidrug-Resistant Acinetobacter baumannii Isolates
    Alharbi, Ahmed Eid
    Alshami, Issam
    [J]. JOURNAL OF PURE AND APPLIED MICROBIOLOGY, 2015, 9 : 497 - 502
  • [4] Combination inhibition activity of chlorhexidine and antibiotics on multidrug-resistant Acinetobacter baumannii in vitro
    Fei Lin
    Bin Yu
    Qinghui Wang
    Mingyong Yuan
    Baodong Ling
    [J]. BMC Infectious Diseases, 21
  • [5] Combination inhibition activity of chlorhexidine and antibiotics on multidrug-resistant Acinetobacter baumannii in vitro
    Lin, Fei
    Yu, Bin
    Wang, Qinghui
    Yuan, Mingyong
    Ling, Baodong
    [J]. BMC INFECTIOUS DISEASES, 2021, 21 (01)
  • [6] In vitro antibacterial activity of eravacycline against multidrug-resistant Acinetobacter baumannii isolates
    Ataman, Merve
    Mataraci-Kara, Emel
    Ozbek-Celik, Berna
    [J]. JOURNAL OF RESEARCH IN PHARMACY, 2021, 25 (05): : 549 - 553
  • [7] A Potential Combination Therapy of Berberine Hydrochloride With Antibiotics Against Multidrug-Resistant Acinetobacter baumannii
    Li, Xiaobo
    Song, Yanqing
    Wang, Lina
    Kang, Guangbo
    Wang, Ping
    Yin, Huabing
    Huang, He
    [J]. FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2021, 11
  • [8] Antimicrobial in vitro activities of ceftazidime-avibactam, meropenem-vaborbactam and plazomicin against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa - a pilot Bulgarian study
    Savov, Encho
    Trifonova, Angelina
    Kovachka, Krassimira
    Kjosseva, Elena
    Strateva, Tanya
    [J]. INFECTIOUS DISEASES, 2019, 51 (11-12) : 870 - 873
  • [9] In vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam alone or in combination with polymyxin B against carbapenem resistant Acinetobacter baumannii
    Rongxin Liang
    Dongxing Wang
    Mingjin Hu
    Yuxia Gu
    Meijun Wang
    Dan Hu
    Mingan Zhu
    Meng Wang
    [J]. The Journal of Antibiotics, 2023, 76 : 540 - 547
  • [10] In vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam alone or in combination with polymyxin B against carbapenem resistant Acinetobacter baumannii
    Liang, Rongxin
    Wang, Dongxing
    Hu, Mingjin
    Gu, Yuxia
    Wang, Meijun
    Hu, Dan
    Zhu, Mingan
    Wang, Meng
    [J]. JOURNAL OF ANTIBIOTICS, 2023, 76 (9): : 540 - 547